Skip to content

Early Detection of Five Common Cancers Using the ctDNA Analysing Test

Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05227261
Acronym
K-DETEK
Enrollment
9057
Registered
2022-02-07
Start date
2022-04-10
Completion date
2024-04-10
Last updated
2025-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Breast, Cancer, Colorectal, Cancer, Gastric, Cancer Liver, Cancer, Lung, Circulating Tumour DNA, Liquid Biopsy

Keywords

Early cancer detection, Circulating Tumour DNA, Liquid biopsy, Vietnam

Brief summary

This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA). Primary objective: To evaluate the performance characteristics of the blood ctDNA test in early detecting cancers. Secondary objectives: * To evaluate the performance characteristics of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests. * To determine the risk of cancers development in the high-risk population, as compared to that in the moderate-risk group.

Detailed description

This is a multi-centre, prospective cohort study recruiting participants aged 40 or above, who present at the Outpatient Clinic of the study hospitals either for periodically follow-up visits for their chronic conditions, or for annually health check-up. The study will be conducted at the Medical Genetic Institute, in collaboration with the University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam and other collaborating hospitals. The potential participants, who satisfy all inclusion/exclusion criteria will be recruited into this study. These potential participants should not have history of cancer before being enrolled in the study. At enrolment, each participant will answer to a pre-designed questionnaire to provide demographic information, past major medical history and clinical warning signs of cancers, and then provide 10mL of blood for analysing the circulating tumour DNA (ctDNA). Each participant will get either ctDNA detected or ctDNA not detected. For those having ctDNA detected in their blood, they will then undergo the screening and diagnostic tests for cancers based on the prediction of tumour origin provided in the test findings report. If the cancers lab-confirmed, patients will then be followed up and managed for their disease according to the guidelines of the Vietnam Ministry of Health and/or the international guidelines on cancers. At 12 months (+/- 1 week) following the enrolment, these patients will be contacted to collect information about their health, in general and their cancer status, in particular. For those having ctDNA detected in their blood but the present of a mass inside participants' body could not be detected using the imaging diagnostic tests; and for those, who don't have ctDNA presenting in blood, phone calls will be made at 6 months (+/- 1 week) and 12 months (+/- 1 week) following the enrolment to collect information related to participants' health status as well as cancer progress (if possible). The enrolment is anticipated to last for approximately 6 months.

Interventions

None listed

Sponsors

Medical University of Ho Chi Minh City
CollaboratorUNKNOWN
Hanoi Medical University
CollaboratorOTHER
Hanoi Oncology Hospital
CollaboratorUNKNOWN
Hue Central Hospital
CollaboratorOTHER
Da Nang Oncology Hospital
CollaboratorUNKNOWN
Thong Nhat Dong Nai General Hospital
CollaboratorUNKNOWN
Dong Nai General Hospital
CollaboratorUNKNOWN
Van Hanh General Hospital
CollaboratorOTHER
Can Tho Oncology Hospital
CollaboratorUNKNOWN
Medic Medical Center
CollaboratorUNKNOWN
Le Van Thinh Hospital
CollaboratorUNKNOWN
People's Hospital 115
CollaboratorUNKNOWN
Xuyen A Hospital
CollaboratorUNKNOWN
Medical Genetics Institute
CollaboratorUNKNOWN
Gene Solutions
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Aged 40 or above at enrolment * Neither clinical suspicion of cancer nor history of confirmed cancer has been reported * Agree to be contacted at 6 months and 12 months following enrolment to collect information about general health status and progress of cancer (if possible) * Provide written informed consent

Exclusion criteria

If a potential participant has any one of the following criteria, he/she will not be able to be enrolled in the study: * History of cancer (cancer has either been confirmed or been treated within the past 3 years) * History of blood transfusion or bone marrow transplantation within the past 3 years * Does not agree to participate in study * The subject has clinical manifestations of pregnant.

Design outcomes

Primary

MeasureTime frame
Positive predictive value, Negative predictive value of the blood ctDNA test in early detecting cancers12 months following enrolment
Sensitivity and specificity of the test in early detecting cancers12 months following enrolment

Secondary

MeasureTime frame
Positive predictive value of the test in determining the origin of tumour, as compared to the findings of the imaging diagnostic tests12 months following enrolment
Rate of cancer development in the high-risk group as compared to the moderate-risk population12 months following enrolment

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026